A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
Clinical trial NCT05252585 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05252585
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2026-10-10
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.